0000899243-23-005687.txt : 20230221 0000899243-23-005687.hdr.sgml : 20230221 20230221163034 ACCESSION NUMBER: 0000899243-23-005687 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220816 FILED AS OF DATE: 20230221 DATE AS OF CHANGE: 20230221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Howze Yalonda CENTRAL INDEX KEY: 0001828153 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 23648658 MAIL ADDRESS: STREET 1: C/O CODIAK BIOSCIENCES, INC. STREET 2: 35 CAMBRIDGEPARK DRIVE, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-949-4100 MAIL ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-16 0 0001659352 Codiak BioSciences, Inc. CDAK 0001828153 Howze Yalonda C/O CODIAK BIOSCIENCES, INC. 35 CAMBRIDGEPARK DRIVE, SUITE 500 CAMBRIDGE MA 02140 0 1 0 0 See Remarks Common Stock 2022-08-16 4 M 0 4857 A 7345 D Common Stock 2022-08-17 4 S 0 1512 2.2135 D 5833 D Common Stock 2023-02-16 4 M 0 4856 A 10689 D Common Stock 2023-02-17 4 S 0 1603 0.5929 D 9086 D Restricted Stock Units 2022-08-16 4 M 0 4857 0.00 D Common Stock 4857 14568 D Restricted Stock Units 2023-02-16 4 M 0 4856 0.00 D Common Stock 4856 9712 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement. Each RSU represents a contingent right to receive one share of common stock. On February 16, 2022, the reporting person was granted 19,425 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary /s/ Yalonda Howze 2023-02-21